Pantothenic Acid Dosage Guide: Protocols, Calculator & Safety
Everything you need to know about Pantothenic Acid dosing — protocols, safety, and where to buy.
Dosage Calculator
Calculate exact dosing for Pantothenic Acid.
Dosing Protocols
Beginner protocol (general health / B-complex insurance). Take a standard B-complex providing 10-25 mg of pantothenic acid (as calcium D-pantothenate) with breakfast daily. A well-formulated B-complex also provides 50-100 mg thiamine, 25-50 mg riboflavin, 25-50 mg niacin or 100-250 mg nicotinamide, 25-50 mg vitamin B6 (as P5P preferred), 300-400 mcg folate (as methylfolate preferred), 100-500 mcg biotin, and 250-500 mcg vitamin B12 (as methylcobalamin preferred). For patients already eating a varied whole-food diet with generous legumes, whole grains, eggs, and mushrooms, a B-complex is insurance rather than necessity, but the downside risk is minimal. Continue indefinitely as preventive maintenance. No monitoring required. Take with food to minimize occasional stomach upset.
For mild skin dryness, irritation, or barrier disruption: topical dexpanthenol 5% cream 1-2 times daily on affected skin. Generally safe for pediatric, adult, and elderly use without medical supervision. For dry nose, diaper rash, or post-procedure recovery, dexpanthenol formulations in the appropriate vehicle (nasal spray, diaper cream, balm) are first-line OTC options.
Intermediate protocol (lipid management or acne support). For mild-to-moderate hyperlipidemia in patients who do not qualify for statins or prefer to attempt dietary and supplement optimization first: pantethine 300 mg twice daily with meals for 4 weeks, then titrate to 300 mg three times daily (900 mg/day total) if baseline LDL or triglycerides remain elevated. Recheck fasting lipid panel at 12 and 24 weeks. Expect a 4-11% reduction in LDL and 8-15% reduction in triglycerides based on Rumberger 2014and earlier trials. If no response at 24 weeks, discontinue — pantethine is not a hidden pharmacologic with dramatic responders; the effect size is what it is. Stack with omega-3 fatty acids 2-4 g EPA+DHA daily and TLC diet for additive benefit. Do not use pantethine as a replacement for statin in patients with established ASCVD, prior MI or stroke, or familial hypercholesterolemia.
For mild-to-moderate acne vulgaris in patients who decline or cannot tolerate topical retinoids, benzoyl peroxide, or oral antibiotics: calcium pantothenate 2-5 g/day divided into 2-3 doses with food. This sits at the low end of the traditional Leung 1995 megadose protocol (which used 10 g/day) but carries a substantially better tolerability profile. Combine with topical benzoyl peroxide 2.5-5% once daily (not counted against pantothenate protocol, just standard care) and patience — acne responses take 8-12 weeks. If no benefit at 12 weeks, discontinue and pursue standard dermatology. Monitor for diarrhea at >3 g/day; dose reduction usually resolves. Patients with moderate-to-severe acne or cystic/nodular disease should not rely on pantothenic acid — pursue tretinoin, isotretinoin, or hormonal therapy under dermatology supervision.
For topical skin/hair indications at intermediate complexity: dexpanthenol 5% cream + hyaluronic acid serum for atopic dermatitis; dexpanthenol nasal spray for post-rhinosurgical or chronic dry nose. Topical dexpanthenol-containing shampoos and conditioners have data for improving hair shaft hydration and manageability but do not promote hair regrowth.
Advanced protocol (highly specific indications). For patients with genetically confirmed PKAN or CoPAN: this is specialist neurology/genetics territory and should not be self-managed. Supportive care includes deutetrabenazine for chorea, botulinum toxin for focal dystonia, deep brain stimulation of the globus pallidus in select cases, and enrollment in trials of pantothenate prodrugs or CoA replacement strategies. Fosmetpantotenate failed its pivotal FORT trial; current active approaches include deoxypantothenate prodrugs and CoA supplementation. Patients and families should work with centers of excellence (NBIA Disorders Association network).
For statin-intolerant patients with ASCVD who cannot achieve LDL goal despite ezetimibe, bempedoic acid, or PCSK9 inhibitor alone: pantethine 900 mg/day as a low-risk adjunct. Not a replacement for primary pharmacology. Monitor fasting lipids at 12-week intervals.
For cognitive/nootropic enthusiasts pursuing cholinergic optimization: calcium pantothenate 500 mg-1 g/day combined with alpha-GPC 300-600 mg/day or CDP-choline 250-500 mg/day as cholinergic substrate and cofactor pairing. This is biochemically rational (acetyl-CoA + choline → acetylcholine) but lacks rigorous clinical trial support for cognitive enhancement in healthy adults. Reasonable to try for 8-12 weeks; discontinue if no subjective benefit.
For athletes experimenting with fatty acid oxidation optimization: pantothenic acid 500-1000 mg/day + L-carnitine 1-2 g/day as a β-oxidation support stack. Biochemical logic is tight but controlled evidence in athletes is thin. Not a shortcut around training volume or nutrition.
For acne patients pursuing the classical megadose Leung protocol: calcium pantothenate 10 g/day divided into 4 doses. Expect GI side effects (loose stools, occasional diarrhea, stomach upset) in a meaningful minority. Continue for 4-6 months minimum. Taper rather than stop abruptly. This protocol is outside contemporary dermatology guidelines and should be undertaken with full awareness that higher-quality therapies exist. Not for adolescents without caregiver involvement.
Stop rules. Discontinue pantothenic acid supplementation if you develop persistent diarrhea not relieved by dose reduction, peripheral edema not attributable to other causes, or if any unexpected symptom correlates with initiation. Stop pantethine if ALT/AST rise significantly (uncommon but monitor at 3-6 months of continuous use). No compound is essential and no supplement is worth serious adverse events.
Commonly Stacked With
Pantothenic acid stacks naturally with the rest of the B-complex and with cofactors that share its metabolic space. The coenzyme A-centered biology connects B5 to virtually every other B vitamin, and sensible combinations amplify rather than redundantly duplicate each other's effects.
Foundational B-complex stacking. A standard B-complex providing 10-100 mg pantothenic acid alongside thiamine, riboflavin, niacin, vitamin B6, biotin, folate, and vitamin B12 is the baseline. The coenzymes produced from these vitamins operate as tightly coupled sets on the central carbon metabolism enzymes — pyruvate dehydrogenase uses thiamine diphosphate, FAD (riboflavin), NAD+ (niacin), and CoA (pantothenic acid) in a single active site. Supplementing B5 in isolation without attending to the others is rarely useful for optimizing cellular energy metabolism.
Pantethine plus niacin for lipid management. Pantethine 600-900 mg/day combined with extended-release niacin 500-1500 mg/day offers complementary mechanisms for LDL and triglyceride reduction: pantethine modestly decreases hepatic cholesterol and fatty acid synthesis at the level of CoA-dependent enzymes, while niacin inhibits hepatic DGAT2 and VLDL secretion. No trial has formally tested the combination for cardiovascular outcomes, but for a patient unable or unwilling to take statins and seeking incremental natural lipid optimization beyond diet, this is a reasonable stack with dramatically better tolerability than statin + niacin combinations.
Pantethine plus omega-3 fatty acids. Pantethine + EPA/DHA omega-3 fatty acids 2-4 g/day produces additive triglyceride lowering in small trials, driven by distinct mechanisms (pantethine increases fatty acid oxidation, omega-3s suppress hepatic VLDL assembly and activate PPARα). This is a particularly rational stack for isolated hypertriglyceridemia.
CoA biology and mitochondrial stack. Pantothenic acid + thiamine + riboflavin + alpha-lipoic acid + CoQ10 + magnesium + L-carnitine forms a "cellular energy infrastructure" stack addressing TCA cycle, β-oxidation, and electron transport. Each component is necessary and nonredundant for mitochondrial function. This is not a treatment for any specific disease but a coherent approach for patients reporting fatigue, metabolic dysfunction, or recovering from illness where mitochondrial support is plausible.
Pantothenic acid and acetylcholine synthesis. Choline acetyltransferase (ChAT) uses acetyl-CoA + choline to synthesize acetylcholine. For cognitive and cholinergic nootropic stacks, pantothenic acid 100-500 mg/day pairs with choline sources (alpha-GPC 300-600 mg/day, CDP-choline/citicoline 250-500 mg/day, or choline bitartrate) to provide both the acetyl donor (via CoA) and the choline substrate. Pantothenic acid is a frequent but often overlooked addition to racetam stacks (piracetam, oxiracetam, aniracetam) where cholinergic support is a theme. Whether meaningful cognitive benefit follows is debated; the biological rationale is sound.
Pantothenic acid and adrenal / steroidogenesis claims. Cortisol, aldosterone, and sex steroid biosynthesis all require cholesterol as the starting scaffold (made from acetyl-CoA) and CoA for acetyl-group transfers throughout the pathway. This is why "adrenal fatigue" marketing gravitates to B5. In practice, steroidogenesis is not pantothenate-rate-limited at normal dietary intakes. However, in chronic stress, critical illness, or post-surgical recovery, a multi-nutrient adrenal support formula (B5 + vitamin C + magnesium + vitamin B6) is low-risk and addresses legitimate micronutrient demand without overselling the "adrenal fatigue" narrative.
Pantothenic acid and acne stacking. Mega-dose calcium pantothenate (5-10 g/day) for acne is sometimes combined with oral zinc 30-50 mg/day (plausible anti-inflammatory and sebocyte benefit, see zinc), vitamin A or retinol equivalents (with careful attention to hepatotoxicity at cumulative doses >10,000 IU/day), and topical benzoyl peroxide or adapalene. Whether the pantothenate is doing independent work vs. riding on the other agents' established effects is unclear. Avoid stacking high-dose B5 with isotretinoin without dermatology supervision; no direct interaction is known but the overlapping effect profile merits caution.
Pantethine and berberine. Berberine 500 mg twice daily plus pantethine 600 mg/day is a natural-product-first cardiometabolic stack for patients in the pre-diabetic/metabolic syndrome zone who want to pursue diet and weight management first. Berberine improves insulin sensitivity and reduces LDL and apoB through AMPK activation and PCSK9 suppression; pantethine adds incremental lipid benefit. Neither replaces statin therapy in established ASCVD.
Dexpanthenol topical and hyaluronic acid. Topical dexpanthenol 5% cream plus hyaluronic acid serum or cream is a routine dermatology combination for atopic dermatitis, xerosis, and post-procedure recovery. The humectant actions are complementary (pantothenate draws water into stratum corneum; hyaluronic acid holds water in the superficial dermis and epidermis). Routine and well-tolerated.
Pantothenic acid and L-carnitine. L-carnitine + pantothenic acid is biochemically logical — CoA activates fatty acids at the mitochondrial outer membrane (acyl-CoA), carnitine then accepts the acyl group for transport across the inner membrane. In athletes and patients with fatigue, 500-1000 mg pantothenic acid + 1-2 g L-carnitine as a β-oxidation support stack is sometimes used, although rigorous trial data on this specific combination are limited.
Pantothenic acid and wound healing. Post-operative or post-traumatic recovery stacks sometimes combine oral pantothenic acid 500-1000 mg with vitamin C 1-2 g, zinc 30 mg, and L-arginine 3-5 g, targeting connective tissue synthesis, immune function, and nitric oxide production during healing. Evidence is more established for vitamin C, zinc, and arginine than for pantothenic acid, but the addition is low-risk.
Pantothenic acid and statin intolerance. Patients with statin-associated muscle symptoms (SAMS) sometimes respond to stacking low-dose statin with CoQ10 100-200 mg + pantothenic acid 100-500 mg + vitamin D3 optimization. The CoQ10 rationale is well-established (statins deplete mevalonate pathway, CoQ10 downstream); pantothenic acid's role here is speculative, supporting CoA-dependent fatty acid oxidation in myocytes.
Avoid unnecessary stacking. Pantothenic acid does not meaningfully combine with creatine (different energy system entirely), does not enhance caffeine effects (no shared mechanism), and does not amplify testosterone-boosting supplements despite marketing claims (basal testosterone is not CoA-rate-limited at dietary intakes). Stack intentionally, not reflexively.
Side Effects & Safety
Contraindications
Pantothenic acid has few absolute contraindications and a small number of relative precautions. Most contraindications in practice are dose-specific (megadose use) rather than universal. Absolute contraindications: - Known hypersensitivity to pantothenic acid, pantethine, dexpanthenol, or excipients of the specific formulation. True type I hypersensitivity is rare but documented in isolated case reports. - Pantothenate kinase-associated neurodegeneration (PKAN) and CoASY-related CoPAN are not contraindications to pantothenic acid per se — affected patients should be under specialist care, and pantothenate itself is not harmful, but it is also not therapeutic because the pathway is blocked downstream. Avoid false-hope megadosing; engage with NBIA specialty centers. Relative precautions: - Acute GI inflammation, active diarrheal illness, or inflammatory bowel disease flare: high-dose pantothenic acid (>2 g/day) can exacerbate diarrhea. Wait until acute illness resolves or use lower doses. - Warfarin, direct oral anticoagulants, or dual antiplatelet therapy: at megadose (>5 g/day) pantothenic acid has been anecdotally reported to marginally prolong bleeding time; clinical significance appears minimal but discuss with prescribing physician before starting gram-level doses. - Chronic kidney disease stage 4-5 or dialysis: pantothenic acid is water-soluble and renally excreted. No clinically significant accumulation or toxicity reported, but megadose use in this population has not been studied. Standard B-complex dosing remains appropriate and is routinely used in dialysis multivitamin protocols (Nephrocaps, Rena-Vite, etc.). - Pregnancy and lactation: megadose pantothenic acid (>1 g/day) has not been studied and should not be pursued without obstetric guidance. Standard AI of 6-7 mg/day via diet or standard prenatal vitamin is safe and recommended. - Pediatric: megadose oral pantothenic acid (>500 mg/day) has not been systematically studied in children and should not be given without pediatric supervision. Standard B-complex pediatric formulations providing age-appropriate doses are routine and safe. - Patients undergoing [biotin](/compound/biotin)-dependent immunoassays: the concern here is with high-dose biotin, not with pantothenic acid. Pantothenic acid at any standard or megadose does not interfere with streptavidin-based laboratory assays. No testing precaution needed. - Concurrent isotretinoin therapy: megadose pantothenic acid for acne should not be used alongside isotretinoin because the isotretinoin alone is a dramatically more effective anti-acne agent and will resolve the condition; stacking pantothenate megadose with isotretinoin adds unnecessary GI side effect burden without clear incremental benefit. - Parkinsonian syndromes and dystonias of unknown etiology: if evaluation for NBIA is ongoing or PKAN is suspected, pursue diagnostic workup (MRI for eye-of-the-tiger sign, PANK2/CoASY/PLA2G6/etc. genetic testing) rather than empirical supplementation. - Pantethine in patients with obstructive cholestatic liver disease: pantethine may modestly affect bile acid metabolism; use with caution and monitor liver enzymes. No well-documented harm, but the patient population is vulnerable. Drug-drug interactions warranting attention are minimal. Routine co-administration with statins (atorvastatin, rosuvastatin, simvastatin), ezetimibe, fibrates, niacin, PCSK9 inhibitors, bempedoic acid, metformin, SGLT2 inhibitors, GLP-1 agonists, sulfonylureas, insulin, ACE inhibitors, ARBs, beta-blockers, calcium channel blockers, and diuretics is safe without dose adjustment. Supplement-supplement considerations: megadose [biotin](/compound/biotin) (>5 mg/day) and megadose pantothenic acid theoretically compete for SMVT-mediated intestinal absorption, but the transporter is saturable and the clinical interaction is negligible at typical supplementation doses. Patients can take both without concern at ordinary doses. Allergic contact dermatitis to topical dexpanthenol is uncommon (reported prevalence 0.3-0.5% in patch testing series). If patch testing reveals panthenol or propylene glycol sensitivity (propylene glycol is a common vehicle excipient), discontinue the specific product and seek alternative formulation. Unlike [niacin](/compound/niacin), pantothenic acid does not cause flushing, does not raise blood glucose or uric acid, does not cause hepatotoxicity at standard doses, and does not require titration. Unlike [vitamin B6](/compound/vitamin-b6), megadose pantothenic acid does not cause peripheral neuropathy (the B6 hazard is unique among B-vitamins). Unlike [biotin](/compound/biotin), pantothenic acid does not produce laboratory assay interference. The compound is remarkably benign across its therapeutic window.
Additional Notes
Pantothenic acid is water-soluble, has no established tolerable upper intake level, and has no established toxic dose in humans at intakes studied up to 10 g/day for several months. Typical dosing ranges by form:
Calcium D-pantothenate oral supplementation: 10-100 mg/day as B-complex insurance or basic supplementation; 500 mg-2 g/day for intermediate therapeutic indications; 5-10 g/day divided into 2-4 doses for mega-dose acne protocols. The adequate intake (AI) established by the Institute of Medicine is 5 mg/day for adults, 6 mg/day during pregnancy, and 7 mg/day during lactation. Children: 1.7 mg/day (age 0-6 months), 1.8 mg/day (7-12 months), 2 mg/day (1-3 years), 3 mg/day (4-8 years), 4 mg/day (9-13 years), 5 mg/day (14+ years).
Pantethine oral: 300-900 mg/day divided. For lipid management, the evidence-supported dose is 600-900 mg/day divided into 2-3 doses with meals. Responses appear at 8-16 weeks. No long-term safety data beyond 24 weeks exist at this dose but practice experience suggests continued tolerability. Pantethine is a different molecular entity from calcium pantothenate on a milligram basis (it delivers 2× pantotheine-equivalents per mole) but both ultimately feed the same CoA pool.
Dexpanthenol topical: 5% cream or ointment, applied 1-4 times daily to affected skin; dexpanthenol 0.5% eye drops or gel; dexpanthenol 5% nasal spray 1-3 times daily. Topical safety is excellent across pediatric and adult populations.
Dexpanthenol intravenous/intramuscular (not commonly used in US; available in Europe): 250-500 mg IV/IM daily for specific post-operative ileus indications in legacy practice. Largely displaced by modern prokinetic agents.
Food sources and RDA context. A varied whole-food diet readily provides 5-10 mg/day: 100 g chicken liver (~7 mg), 2 large eggs (~1.4 mg), 1 avocado (~2 mg), 1 cup sunflower seeds (~10 mg), 1 cup mushrooms (~2.5 mg), 1 cup yogurt (~1.3 mg), 1 medium sweet potato (~1 mg), 100 g salmon (~1.6 mg), 1 cup broccoli (~0.5 mg). Whole grains, legumes, and organ meats are generous; refined grains and highly processed foods are poor sources.
Bioavailability. Oral pantothenate absorption is efficient at dietary doses (50-80%) via saturable SMVT-mediated uptake; at supraphysiologic doses, passive diffusion contributes and absolute absorption fraction falls but absolute amount absorbed continues to rise. Calcium pantothenate and free pantothenic acid have equivalent bioavailability in practice. Pantethine is well-absorbed and rapidly reduced to pantetheine intracellularly, then phosphorylated into the CoA pathway bypassing the earliest PANK-rate-limited step. Dexpanthenol taken orally is rapidly oxidized to pantothenate and behaves identically; the main distinction is topical formulation advantages.
Timing. No specific time-of-day requirement. Take with food to minimize occasional stomach upset. Splitting doses of pantethine across meals may improve absorption and reduce GI events.
Interactions with drugs. Pantothenic acid has no known clinically significant CYP-mediated interactions. No dose adjustment needed for statins, fibrates, niacin, ezetimibe, bempedoic acid, PCSK9 inhibitors, metformin, or common cardiovascular medications. No interaction with warfarin at typical doses; theoretical bleeding time prolongation at >5 g/day has been reported anecdotally without confirmed clinical relevance.
Special populations. Pregnancy: standard AI of 6 mg/day via diet or B-complex; avoid megadose supplementation without obstetric guidance. Lactation: 7 mg/day AI. Pediatric: age-adjusted AI via diet and pediatric multivitamin; megadose indications (acne protocols) are not established in children. Elderly: standard dosing; renal impairment does not require dose adjustment at supplementation ranges. Patients on dialysis: pantothenic acid is water-soluble and dialyzable; standard B-complex replacement is routine in dialysis practice.
Monitoring. No routine monitoring required at standard doses. For pantethine at 600-900 mg/day, consider fasting lipid panel at 12 and 24 weeks to document response and liver enzymes annually if continued long-term. For megadose calcium pantothenate (5-10 g/day), monitor for GI symptoms and reassess indication at 6-month intervals.
Frequently Asked Questions
What is the recommended Pantothenic Acid dosage?
Dosage for Pantothenic Acid varies by protocol. Consult a qualified healthcare provider.
How often should I take Pantothenic Acid?
Administration frequency depends on the specific protocol. Consult current research literature.
Does Pantothenic Acid need to be cycled?
Cycling requirements depend on the protocol. Follow established research guidelines.
What are Pantothenic Acid side effects?
Pantothenic acid has one of the cleanest safety profiles in the vitamin world. The Institute of Medicine has not set a tolerable upper intake level for pantothenic acid because human toxicity data are essentially absent. Calcium pantothenate at doses up to 10 g/day has been taken by acne patients for months without serious adverse effects reported in the Leung 1995 open-label series. Pantethine at 900 mg/day was well-tolerated in Rumberger 2014with adverse event rates comparable to placebo. Dexpanthenol topical (5% cream, nasal spray, ophthalmic ointment) is considered pharmacologically benign for broad use in pediatric, adult, and elderly populations. GI effects are the most commonly reported. Doses above 2-5 g/day of calcium pantothenate can cause mild to moderate diarrhea — osmotic in origin, not a sign of toxicity, and usually resolves with dose reduction. Nausea and mild stomach upset occur occasionally, more often on empty stomach. Pantethine at 600-900 mg/day has been reported to cause occasional GI upset in less than 10% of users across trials. Water retention and peripheral edema have been reported anecdotally at very high doses (>5 g/day) in acne case series, usually mild and reversible with discontinuation. The mechanism is not established. Skin reactions to topical dexpanthenol are rare. Contact dermatitis has been documented in isolated case reports at a rate of approximately 0.3-0.5% in patch testing series; patients with known sensitivity to panthenol or related compounds (propylene glycol contaminants in commercial preparations can be the actual allergen) should avoid. Bleeding risk at very high doses. Pantothenic acid in gram quantities has been reported to marginally prolong bleeding time in isolated reports; the mechanism is unclear and clinical significance appears minimal, but patients on warfarin, direct oral anticoagulants, or dual antiplatelet therapy should discuss before taking gram-level doses. Routine supplementation at 10-100 mg/day carries no such concern. Drug and nutrient interactions are minimal. As discussed in [biotin](/compound/biotin), SMVT-mediated co-absorption means that theoretically very high biotin intakes could competitively inhibit pantothenate uptake and vice versa, but clinically meaningful interference has not been documented at supplementation doses used in practice. Pantothenic acid has no known interactions with cytochrome P450 enzymes and does not significantly affect drug metabolism. Pantethine has no documented interactions with statins, fibrates, or niacin, making it a reasonable stacking candidate for patients seeking incremental lipid benefit (see [stacking notes](/compound/niacin)). Pantethine taken concurrently with aspirin and nonsteroidal anti-inflammatories does not increase bleeding risk in reported trials. Pregnancy and lactation. Pantothenic acid is considered safe during pregnancy at standard intakes; the AI is 6 mg/day during pregnancy and 7 mg/day during lactation, reflecting the need for fetal CoA biosynthesis. Megadose supplementation during pregnancy has not been studied and is not recommended. Dexpanthenol topical, including nipple creams for breastfeeding mothers, is widely considered safe for both mother and infant; topical use has been cleared in standard pregnancy safety references. Pediatric dosing. Pantothenic acid in pediatric multivitamins at 3-10 mg/day is routine. Dexpanthenol diaper cream is broadly used in infants without safety concerns. Megadose oral pantothenic acid has not been systematically studied in children and should not be given outside of supervised care for defined indications. Elderly populations. Absorption efficiency of pantothenic acid declines modestly with age but clinically meaningful deficiency is rare. Standard 5-20 mg/day in a B-complex is appropriate. Renal impairment. Pantothenic acid is water-soluble and renally excreted; in severe chronic kidney disease (stage 4-5, dialysis), accumulation is theoretically possible but has not been associated with clinical toxicity. Standard doses remain safe. Laboratory interference. Unlike [biotin](/compound/biotin), pantothenic acid does not interfere with streptavidin-based immunoassays, and no FDA alert exists regarding pantothenate dosing causing lab test inaccuracies. Pantethine reportedly does not affect standard lipid panel accuracy. Overall, pantothenic acid is among the safest vitamins. The primary practical caution is simply to avoid unnecessary megadosing — there is no proven long-term benefit to taking 5-10 g/day indefinitely, even though short-term tolerability appears good. B-complex or standalone 10-100 mg/day is the evidence-free-but-sensible sweet spot for general supplementation; pantethine 600-900 mg/day is appropriate for lipid indication; dexpanthenol topical is appropriate for skin indications.
Where can I buy Pantothenic Acid?
Visit our vendor directory to find trusted sources for Pantothenic Acid.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
